a Department of Nephrology and Hypertension, University Medical Center Utrecht and Regenerative Medicine Utrecht , Utrecht University , Utrecht , The Netherlands.
b Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences , Utrecht University , Utrecht , The Netherlands.
Expert Rev Med Devices. 2018 May;15(5):323-336. doi: 10.1080/17434440.2018.1462697. Epub 2018 Apr 20.
Since the advent of peritoneal dialysis (PD) in the 1970s, the principles of dialysis have changed little. In the coming decades, several major breakthroughs are expected.
Novel wearable and portable dialysis devices for both hemodialysis (HD) and PD are expected first. The HD devices could facilitate more frequent and longer dialysis outside of the hospital, while improving patient's mobility and autonomy. The PD devices could enhance blood purification and increase technique survival of PD. Further away from clinical application is the bioartificial kidney, containing renal cells. Initially, the bioartificial kidney could be applied for extracorporeal treatment, to partly replace renal tubular endocrine, metabolic, immunoregulatory and secretory functions. Subsequently, intracorporeal treatment may become possible.
Key factors for successful implementation of miniature dialysis devices are patient attitudes and cost-effectiveness. A well-functioning and safe extracorporeal blood circuit is required for HD. For PD, a double lumen PD catheter would optimize performance. Future research should focus on further miniaturization of the urea removal strategy. For the bio-artificial kidney (BAK), cost effectiveness should be determined and a general set of functional requirements should be defined for future studies. For intracorporeal application, water reabsorption will become a major challenge.
自 20 世纪 70 年代腹膜透析(PD)问世以来,透析原理基本没有改变。在未来几十年,预计将出现几项重大突破。
首先有望出现用于血液透析(HD)和 PD 的新型可穿戴式和便携式透析设备。HD 设备可促进更频繁和更长时间的院外透析,同时提高患者的移动性和自主性。PD 设备可增强血液净化并提高 PD 的技术存活率。离临床应用更远的是生物人工肾,其中包含肾细胞。最初,生物人工肾可用于体外治疗,部分替代肾小管内分泌、代谢、免疫调节和分泌功能。随后,可能实现体内治疗。
成功实施微型透析设备的关键因素是患者的态度和成本效益。HD 需要功能良好且安全的体外血液回路。对于 PD,双腔 PD 导管将优化性能。未来的研究应集中在进一步缩小尿素清除策略上。对于生物人工肾(BAK),应确定成本效益,并为未来的研究定义一套通用的功能要求。对于体内应用,水的再吸收将成为一个主要挑战。